BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Blogs » BioWorld Perspectives » ‘Indirect’ Fat Clogging NIH’s Arteries

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / NIH

‘Indirect’ Fat Clogging NIH’s Arteries

March 12, 2013
By Mari Serebrov

In the days before the sequester tightened Washington’s belt, the National Institutes of Health (NIH) and several other federal agencies sent up warning shots of just what was at stake. Under the automatic budget cuts intended to put the national deficit on a strict diet, the NIH expected to lose $1.6 billion from its 2013 fiscal budget.

If the sequester stayed in place, NIH Director Francis Collins said the agency would give "hundreds and hundreds" fewer grants than it would have awarded otherwise, slowing down important research. Speaking at a news conference, Collins said the NIH was trying to avoid employee furloughs, but he couldn't promise they wouldn’t occur.

That’s when someone asked a question that others were likely thinking: “Doesn’t the NIH have any fat it can trim?”

“No,” was the reply, especially since the sequester was falling on the heels of several years of nearly flat budgets for the agency. Collins pointed out that because of those flat budgets, the NIH has lost about 20 percent of its spending power in recent years.

Collins painted a similarly bleak picture last year when he testified before a House subcommittee. Even without the sequester, researchers had only a 17 percent chance of getting NIH grant funding, one of the lowest rates in history, he told the Energy and Commerce's Health Subcommittee. In years past, a researcher had a 30 percent chance at funding.

Today, the average age of a researcher getting a first grant is 43. That fact is enough to send young scientists into other careers, depleting the next generation of researchers and jeopardizing the nation’s status as a leader in medical R&D.

While the numbers are discouraging, there is something that would enable the NIH to fund more researchers and stretch its limited research dollars, even under sequestration. The solution? Limit the indirect costs universities can take from agency grants to cover facilities and administration (F&A).

While many foundations spend less than 25 percent of their grants on indirect costs, some universities are spending up to 95 percent on overhead, Rep. Tim Murphy (R-Pa.) said at the subcommittee hearing last year. Repeating a previous conversation with Collins, Murphy listed several private universities that charge excessive indirect costs on NIH grants but spend little of their own money on research. For instance, Harvard University, which has an endowment bigger than the NIH budget, applied 75 percent of its NIH funding to overhead costs and spent zero of its own funding, the congressman said.

Such practices aren’t limited to NIH grants, as the F&A rates for research grants are calculated in accordance with federal-wide guidelines issued by the Office of Management and Budget. “F&A cost rates are negotiated and established by the federal government to ensure that they are fair and equitable and that the federal government pays its fair share of these costs,” NIH told BioWorld recently.

Given current budget constraints and the fact that many universities are making money by licensing the intellectual property resulting from NIH-funded research, it may be time to rethink the government’s “fair share” of those F&A costs. Putting tighter caps on indirect costs would give the NIH more money to fund its core mission of research rather than subsidizing universities that will profit from that research.

Editor's note: How much NIH grant money should go toward indirect costs such as facilities and administration? Cast your vote at bioworld.com. Look for our poll on the bottom, right side.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing